Terms: = Endocrine gland cancer AND ZNF198, Q9UBW7, SCLL, RAMP, MYM, FIM, 7750 AND Treatment
6 results:
1. Y-Box Binding Protein 1: Unraveling the Multifaceted Role in cancer Development and Therapeutic Potential.
Dinh NTM; Nguyen TM; Park MK; Lee CH
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255791
[TBL] [Abstract] [Full Text] [Related]
2. Pathological findings and long-term prognosis in Korean BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Kang OJ; Lee SW; Kim JH; Park JY; Suh DS; Kim DY; Kim JH; Kim YM; Kim YT
Int J Gynecol Cancer; 2023 Nov; 33(11):1743-1749. PubMed ID: 37541685
[TBL] [Abstract] [Full Text] [Related]
3. Development and validation of a survival prediction model and risk stratification for pancreatic neuroendocrine neoplasms.
Lu Z; Li T; Liu C; Zheng Y; Song J
J Endocrinol Invest; 2023 May; 46(5):927-937. PubMed ID: 36394822
[TBL] [Abstract] [Full Text] [Related]
4. Strategies for CT tissue segmentation for Monte Carlo calculations in nuclear medicine dosimetry.
Braad PE; Andersen T; Hansen SB; Høilund-Carlsen PF
Med Phys; 2016 Dec; 43(12):6507. PubMed ID: 27908147
[TBL] [Abstract] [Full Text] [Related]
5. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract] [Full Text] [Related]
6. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
Dragovich T; Laheru D; Dayyani F; Bolejack V; Smith L; Seng J; Burris H; Rosen P; Hidalgo M; Ritch P; Baker AF; Raghunand N; Crowley J; Von Hoff DD
Cancer Chemother Pharmacol; 2014 Aug; 74(2):379-87. PubMed ID: 24939212
[TBL] [Abstract] [Full Text] [Related]
